CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

por Turner, Joel G., Dawson, Jana, Emmons, Michael F., Cubitt, Christopher L., Kauffman, Michael, Shacham, Sharon, Hazlehurst, Lori A., Sullivan, Daniel M.
Publicado 2013

Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

por Turner, Joel G., Dawson, Jana L., Grant, Steven, Shain, Kenneth H., Dalton, William S., Dai, Yun, Meads, Mark, Baz, Rachid, Kauffman, Michael, Shacham, Sharon, Sullivan, Daniel M.
Publicado 2016

Rapid Screening of Novel Agents for Combination Therapy in Sarcomas

por Cubitt, Christopher L., Menth, Jiliana, Dawson, Jana, Martinez, Gary V., Foroutan, Parastou, Morse, David L., Bui, Marilyn M., Letson, G. Douglas, Sullivan, Daniel M., Reed, Damon R.
Publicado 2013

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myel...

por Turner, Joel G., Kashyap, Trinayan, Dawson, Jana L., Gomez, Juan, Bauer, Alexis A., Grant, Steven, Dai, Yun, Shain, Kenneth H., Meads, Mark, Landesman, Yosef, Sullivan, Daniel M.
Publicado 2016